CliffBio
small molecule

VYBRIQUE

SILDENAFIL CITRATE

Loss of exclusivityDecember 2033latest FDA-listed patent expiry
CompanyIBSA Institut Biochimique →View the full company profile on CliffBio

Drug detail

Brand nameVYBRIQUE
Active ingredientSILDENAFIL CITRATE
StrengthEQ 25MG BASE
Dosage formFILM
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2025
Marketing statusRX

Listed patents

PatentExpiresType
11123287December 2033product

Regulatory exclusivity

CodeExpires
NPDecember 2028

More from IBSA Institut Biochimique

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VYBRIQUE patent cliff — loss of exclusivity December 2033 | CliffBio